Investigation of Pharmacokinetics, Safety, Tolerability and Pharmacodynamic Effects of a Single Oral 10 mg BAY1101042 MR Tablet Dose in Male and Female Subjects With Renal Impairment and in Age-, Gender-, and Weight- Matched Healthy Subjects in a Single Center, Non-controlled, Open-label, Observational Design
Phase of Trial: Phase I
Latest Information Update: 12 Apr 2019
Price : $35 *
At a glance
- Drugs BAY 1101042 (Primary)
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors Bayer
- 10 Apr 2019 Status changed from active, no longer recruiting to completed.
- 11 Mar 2019 Planned End Date changed from 22 Jan 2019 to 13 Mar 2019.
- 07 Dec 2018 Planned End Date changed from 22 Nov 2018 to 22 Jan 2019.